ACLY and metabolic dysfunction-associated steatotic liver disease: In animal models, BemA, by inhibiting ACLY, has demonstrated efficacy in reducing hepatic steatosis and preventing the progression of MASLD to MASH by impairing the activation and proliferation of HSC, thereby reducing fibrosis.